Spero Therapeutics (SPRO US)
SPRO US$1.17
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 1.17
- Change
- ▲ 0.03 (2.63)
- Bid / Ask
- 1.17 - 1.18
- Volume
- 59,026
- Turnover
- 64,784
- Open
- 1.18
- Day Range
- 1.13 - 1.18
- VWAP
- 1.16
- Prev Close
- 1.14
- Last Trade
- 28/10 3:59pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 58,234,827
- NTA/Share
- 1.05
- Last Dividend
- —
- Dividend Ex Date
- —
- Dividend Pay Date
- —
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 59.62
- EBITDA
- 6.32
- Profit
- 8.57
- Earnings Per Share (EPS)
- 0.15
- Dividend Per Share (DPS)
- —
- Yield %
- 0.00
- Market Cap
- 68.13
- Price to Earnings Ratio (P/E)
- 8.36
Estimates (USD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- 0.00
- EBITDA
- —
- Profit
- -51.50
- Earnings Per Share (EPS)
- -0.88
- Dividend Per Share (DPS)
- —
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Undervalued
- Economic Moat
- None
- Financial Health
- Strong
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 23 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 0.98 Fair value 1.89 One-star price 3.64
Morningstar Quantitative Rating as of 23 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 1.89
- Price / Fair Value
- 0.59
- Valuation
- Undervalued
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 23 OCT 2026. The slider runs from the five-star price (0.98) to the one-star price (3.64).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 1.11 |
| Price - 12 month high | 3.08 |
| Price - 12 month low | 1.08 |
| Pricing date | 22 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 0.41 |
| Market capitalization | 64.64 |
| 12 Month High price date | 27 MAY 2026 |
| 12 Month Low price date | 24 JUL 2026 |
| Volume - avg. trading volume for the last 3 months | 0.90 |
| Price - 1 Day % Change | -1.77% |
| Price - 13 week price percent change | -4.31% |
| Price - 26 week price percent change | -60.36% |
| Price - 5 Day % Change | 0.91% |
| Price - 52 week price percent change | -49.55% |
| Price - YTD price percent change | -51.10% |
| Price % Change Month To Date | -11.90% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | 0.150 |
| EPS excluding extraordinary items - trailing 12 month | 0.140 |
| EPS Normalized - most recent fiscal year | 0.235 |
| Revenue/share - most recent fiscal year | 1.010 |
| Revenue/share - trailing 12 month | 0.716 |
| Book value per share - most recent fiscal year | 1.046 |
| Book value per share - most recent quarter | 0.760 |
| Book value (tangible) per share - most recent fiscal year | 1.046 |
| Book value (tangible) per share - most recent quarter | 0.760 |
| Cash per share - most recent fiscal year | 0.714 |
| Cash per share - most recent quarter | 0.873 |
| Cash Flow per share - most recent fiscal year | 0.246 |
| Cash Flow per share - trailing 12 month | 0.215 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.000 |
| EBITD per share - trailing 12 month | 0.100 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 0.150 |
| EPS Basic excluding extraordinary items - trailing 12 month | 0.140 |
| EPS including extraordinary items - most recent fiscal year | 0.150 |
| EPS including extraordinary items - trailing 12 month | 0.140 |
| Free Cash Flow per share - trailing 12 month | 0.215 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | 7.93 |
| P/E Normalized, most recent fiscal year | 5.54 |
| Price to sales - most recent fiscal year | 1.55 |
| Price to Tangible Book - most fiscal year | 1.46 |
| Price to Free Cash Flow per Share - most recent fiscal year | 5.16 |
| Price to Cash Flow per share - trailing 12 month | 5.16 |
| Price to Book - most recent fiscal year | 1.46 |
| P/E excluding extraordinary items high, trailing 12 months | 19.07 |
| P/E excluding extraordinary items low, trailing 12 months | 4.26 |
| Net Debt, LFI | -48.73 |
| Net Debt, LFY | -37.37 |
| Dividend Yield - 5 Year Average | — |
| Dividend Yield - indicated annual dividend divided by closing price | — |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 0.00% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | 14.53 |
| LT debt/equity - most recent fiscal year | 1.59% |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | 4.91% |
| LT debt/equity - most recent quarter | 0.10% |
| Total debt/total equity - most recent quarter | 4.62% |
| Free Cash Flow - trailing 12 month | 12.91 |
| Payout ratio - trailing 12 month | — |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 59.62 |
| Revenue - trailing 12 month | 42.96 |
| EBITD - most recent fiscal year | 6.32 |
| EBITD - trailing 12 month | 6.02 |
| Earnings before taxes - most recent fiscal year | 8.83 |
| Earnings before taxes - trailing 12 month | 7.64 |
| Net Income available to common - most recent fiscal year | 8.57 |
| Net Income available to common - trailing 12 months | 7.38 |
| Earnings before taxes Normalized - most recent fiscal year | 14.00 |
| Net Income Available to Common, Normalized - most recent fiscal year | — |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 0.20 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | 14.38% |
| Net Profit Margin % - trailing 12 month | 17.18% |
| Operating margin - 1st historical fiscal year | 12.01% |
| Operating margin - trailing 12 month | 15.39% |
| Pretax margin - trailing 12 month | 17.79% |
| Pretax margin - 1st historical fiscal year | 14.82% |
| Operating Margin - 5 year average | -630.66% |
| Pretax Margin - 5 year average | -645.68% |
| Free Operating Cash Flow/Revenue, 5 Year Average | -802.61% |
| Free Operating Cash Flow/Revenue, TTM | 30.05% |
| Net Profit Margin - 5 year average | -646.30% |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | 11.48% |
| Return on average assets - trailing 12 month | 12.43% |
| Return on average equity - most recent fiscal year | 21.62% |
| Return on average equity - trailing 12 month | 17.13% |
| Return on average assets - 5 year average | -27.20% |
| Return on average equity - 5 year average | -47.51% |
| Net Income/employee - most recent fiscal year | 342,880.00 |
| Revenue/employee - most recent fiscal year | 2,384,760.00 |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | 197.00% |
| EPS growth rate, 5 year | — |
| Growth rate% - dividend, 3 year | — |
| Revenue/share (5 yr growth) | 144.64% |
| Growth rate% - Revenue, 3 year | 7.06% |
| Growth rate% - EPS, 3 year | — |
| Book value per share growth rate, 5 year | -25.35% |
| Capital Spending growth rate, 5 year | — |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | — |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | ||||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | DEC 21 | DEC 22 | DEC 23 | DEC 24 | DEC 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
